>Emergent BioSolutions, Inc., announced on Friday that it has made Barry Labinger the new executive vice president of the company. Labinger also became the president of Emergent BioSolutions' biosciences division. Under his new role, Labiner will be responsible for the development, manufacturing and commercialization of biosciences product candidates. "Barry brings to Emergent over two decades of extensive biopharmaceutical experience that encompasses general management, commercialization, and business development - core competencies that are integral to achieving the goals we have set in our growth plan," Daniel J. Abdun-Nabi, Emergent's president and chief executive officer, said. "As we look to expand our portfolio with specialized products that address the needs of hospitals and healthcare providers, Barry's expertise will help greatly in establishing Emergent in the commercial marketplace." Labinger previously served as the executive vice president and chief commercial officer at Human Genome Sciences, Inc., from 2005 to 2012. Before this, Labinger was the global head of 3M Pharmaceuticals from 2002 to 2005 and the senior vice president and general manager commercial operations at Immunex Corp. from 2000 to 2002. Emergent BioSolutions is a pharmaceutical company that offers specialized products to healthcare providers and governments. Their products are aimed at addressing medical needs and emerging health threats.